Drug class profile · refreshed daily from federal data

General Anesthetic

10 molecules in this class, — combined CY2024 Part D spend across — claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the General Anesthetic class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 10tracked in Part D
CY24 Part D spend: —combined across class
Total Rx claims: —— unique beneficiaries
Generic mfrs (active): 33across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Amidate(Tm) Etomidate

— Part D claims (CY24) · First FDA approval: 2020-03-31

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Desflurane

Brand: SUPRANE · — Part D claims (CY24) · First FDA approval: 1992-09-18

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Etomidate

Brand: Amidate · — Part D claims (CY24) · First FDA approval: 2005-07-26

7 generic mfrs Active FDA shortage

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Etomidate Injection

Brand: Etomidate · — Part D claims (CY24) · First FDA approval: 2017-05-20

Brand-only (no generics) Active FDA shortage

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Etomidate Injection, Solution

— Part D claims (CY24) · First FDA approval: 2023-09-25

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Isoflurane

Brand: FORANE · — Part D claims (CY24) · First FDA approval: 1979-12-18

4 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ketamine

Brand: KETALAR · — Part D claims (CY24) · First FDA approval: 1996-07-01

7 generic mfrs Discontinued

Low NADAC$0.556

→

Avg plan cost$1.17

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Propofol

Brand: Diprivan · — Part D claims (CY24) · First FDA approval: 2006-04-03

9 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Propofol Injectable Emulsion

— Part D claims (CY24) · First FDA approval: 2018-11-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Sevoflurane

Brand: Sojourn · — Part D claims (CY24) · First FDA approval: 1995-06-07

5 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.